These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: PPARγ agonist pioglitazone improves scopolamine-induced memory impairment in mice.
    Author: Xiang GQ, Tang SS, Jiang LY, Hong H, Li Q, Wang C, Wang XY, Zhang TT, Yin L.
    Journal: J Pharm Pharmacol; 2012 Apr; 64(4):589-96. PubMed ID: 22420664.
    Abstract:
    OBJECTIVES: This study was conducted to evaluate the effects of exposure to pioglitazone, a peroxisome proliferator-activated receptor agonist, on cognitive impairment induced by scopolamine, a muscarinic antagonist, in mice. METHODS: Pioglitazone (9mg/kg, 18mg/kg) was orally administered for 9 days at 30min before intraperitoneal injection with scopolamine (0.8mg/kg, i.p.). Cognitive function was evaluated by the passive avoidance test and the Morris water maze test on the 10th day after treatment. Changes in cholinergic system reactivity were also examined by measuring the acetylcholine, acetylcholinesterase and choline acetyltransferase in the hippocampus and cortex. KEY FINDINGS: Scopolamine injection induced impaired performance in the passive avoidance test and the water maze test and severe decrease of cholinergic system reactivity, as indicated by reduced acetylcholine levels, decreased choline acetyltransferase activity and increased acetylcholinesterase activity. Daily administration of pioglitazone significantly increased step-through latency in passive avoidance test, and significantly decreased the escape latency, and increased the time spent in the platform quadrant in the Morris water maze test. Pioglitazone also protected against scopolamine-induced cholinergic system deficit, including reduced acetylcholine levels, decreased choline acetyltransferase activity and increased acetylcholinesterase activity in the hippocampus or cortex. CONCLUSIONS:   Pioglitazone demonstrates a significant neuroprotective effect against scopolamine-induced cholinergic system deficit and cognitive impairment.
    [Abstract] [Full Text] [Related] [New Search]